Before the end of the year, France will be able to count on a new weapon in the face of Covid-19: the Minister of Health, Olivier Véran, has announced the order of 50,000 doses of the anti-covid pill from Merck.
Molnupiravir is the name of the antiviral drug developed by the American laboratory Merck to fight against Covid-19. Tested on nearly 800 patients, this pill would halve the risk of hospitalization in the event of contamination. The first encouraging results have convinced the French government, even if the cost of this treatment should be high: around 600 euros per dose. But before it is put on the market, it still has to go through an authorization procedure from the European health authorities.